

# Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1 $\beta$ release through pyrophosphates

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.

Pablo Pelegrin<sup>1,\*</sup> and Annmarie Surprenant\*

Faculty of Life Sciences, University of Manchester, Manchester, UK

In acute inflammation, extracellular ATP activates P2X<sub>7</sub> ion channel receptors (P2X<sub>7</sub>R) on M1 polarized macrophages to release pro-inflammatory IL-1 $\beta$  through activation of the caspase-1/nucleotide-binding domain and leucine-rich repeat receptor containing pyrin domain 3 (NLRP3) inflammasome. In contrast, M2 polarized macrophages are critical to the resolution of inflammation but neither actions of P2X<sub>7</sub>R on these macrophages nor mechanisms by which macrophages switch from pro-inflammatory to anti-inflammatory phenotypes are known. Here, we investigated extracellular ATP signalling over a dynamic macrophage polarity gradient from M1 through M2 phenotypes. In macrophages polarized towards, but not at, M2 phenotype, in which intracellular IL-1 $\beta$  remains high and the inflammasome is intact, P2X<sub>7</sub>R activation selectively uncouples to the NLRP3-inflammasome activation but not to upstream ion channel activation. In these intermediate M1/M2 polarized macrophages, extracellular ATP now acts through its pyrophosphate chains, independently of other purine receptors, to inhibit IL-1 $\beta$  release by other stimuli through two independent mechanisms: inhibition of ROS production and trapping of the inflammasome complex through intracellular clustering of actin filaments.

*The EMBO Journal* (2009) 28, 2114–2127. doi:10.1038/emboj.2009.163; Published online 18 June 2009

**Subject Categories:** signal transduction; immunology

**Keywords:** alternative macrophage activation; caspase-1; inflammation; NLRP-3 inflammasome; P2X<sub>7</sub> receptor

## Introduction

Macrophages are critical to both the innate and adaptive immune response; they must develop and respond to rapid changes in the microenvironment. Inflammation resulting from pathogens or tissue damage activates resident macrophages to initiate or increase production of pro-inflammatory cytokines and other inflammatory mediators. However, macrophages are equally critical in the resolution of inflammation by producing anti-inflammatory cytokines and chemokines and by increased phagocytic activity. On the basis of Th1/Th2 polarization concepts (Romagnani, 2000), phenotypically polarized macrophages are now generally termed pro-inflammatory M1 or classically activated, and anti-inflammatory M2 or alternatively activated (Gordon, 2003; Martinez *et al*, 2008). Experimentally, macrophages *in vitro* are polarized to the M1 state by treatment with IFN- $\gamma$  and inducers of TNF- $\alpha$ , such as lipopolysaccharide (LPS) or other bacterial products (Ehrt *et al*, 2001; Gordon, 2003). M1 macrophages induce synthesis and upregulation of several pro-inflammatory cytokines and chemokines, key among these are TNF- $\alpha$ , IL-12, IL-6, CCL2 and IL-1 $\beta$ , as well as increased production of reactive oxygen species (ROS) and nitrogen intermediates (Gordon, 2003; Martinez *et al*, 2008). At the other extreme, macrophages are polarized to the M2 state by stimuli such as IL-4, IL-13, IL-10 or glucocorticoid hormones (Gordon, 2003; Martinez *et al*, 2008). M2 macrophages upregulate scavenger, mannose and galactose receptors, IL-1 receptor antagonist and downregulate IL-1 $\beta$  and other pro-inflammatory cytokines (Gordon, 2003; Scotton *et al*, 2005; Martinez *et al*, 2006, 2008). Very high levels of IL-1 $\beta$  are present in M1 polarized macrophages because of activation of the NF- $\kappa$ B and MAPK cascades (Dinarello, 1996) but no IL-1 $\beta$  protein is found in M2 polarized macrophages (Scotton *et al*, 2005; Martinez *et al*, 2006).

IL-1 $\beta$  processing and release is a tightly regulated process involving a multiprotein complex, the caspase-1 inflammasome (Martinon *et al*, 2002). IL-1 $\beta$  is synthesized as a 34 kD precursor protein that is cleaved to its biologically active 17 kD form by the protease caspase-1. Inactive caspase-1 is constitutively present in both M1 and M2 macrophages and is activated in M1 macrophages by self-cleavage that occurs in the inflammasome complex. Distinct caspase-1 inflammasomes have been distinguished based on their protein composition and means of activation (Mariathasan *et al*, 2004, 2006; Kanneganti *et al*, 2006; Martinon *et al*, 2006). The nucleotide-binding domain and leucine-rich repeat receptor containing pyrin domain 3 (NLRP3) inflammasome can be activated by specific microbial motifs (pathogen-associated molecular patterns, PAMPs), by *Escherichia coli* and *Staphylococcus aureus* bacteria, by microbial toxins such as

\*Corresponding authors. P Pelegrin, Inflammation and Experimental Surgery Group, University Hospital 'Virgen de la Arrixaca'-Fundación Formación e Investigación Sanitarias Región de Murcia (FFIS), 30120 El Palmar, Murcia, Spain. Tel.: +34 968369317; Fax: +34 968369364; E-mail: pablo.pelegrin@ffis.es or A Surprenant, Faculty of Life Science, University of Manchester, Michael Smith Building D3315, Manchester M13 9PT, UK. Tel.: +44 1613060505; Fax: +44 1612751498; E-mail: a.surprenant@manchester.ac.uk

<sup>1</sup>Present address: Inflammation and Experimental Surgery Group, University Hospital 'Virgen de la Arrixaca'-FFIS, Murcia, Spain

Received: 9 April 2009; accepted: 26 May 2009; published online: 18 June 2009

nigericin and maitotoxin (MTX), by uric acid crystals and by extracellular ATP acting through the ATP-gated plasma membrane ion channel, the P2X<sub>7</sub> receptor (P2X<sub>7</sub>R) (Mariathasan *et al*, 2004, 2006; Martinon *et al*, 2006; Pétrilli *et al*, 2007). P2X<sub>7</sub>R activation by ATP released at sites of inflammation is currently the only well-established physiological stimulator of the NLRP3 inflammasome (Ferrari *et al*, 2006; Mariathasan *et al*, 2004, 2006) and, as such, it has become an attractive target for development of new anti-inflammatory drugs (Pelegrin, 2008). P2X<sub>7</sub>R gene -deleted mice show anti-inflammatory phenotypes in models of neuropathic and inflammatory pain (Labasi *et al*, 2002; Chessell *et al*, 2005) and a recently developed P2X<sub>7</sub>R antagonist has shown reduced joint swelling, tenderness and pain perception in Phase II clinical trials in patients with rheumatoid arthritis (McInnes *et al*, 2007). The P2X<sub>7</sub>R is a highly unusual ion channel predominantly expressed in macrophage and microglia; its activation opens a cationic channel with high permeability to calcium but it also forms within seconds a larger pore permeable to small molecules up to 900 Da (Ferrari *et al*, 2006; Pelegrin and Surprenant, 2006; Pelegrin *et al*, 2008). All downstream sequelae of P2X<sub>7</sub>R activation except for the initial cation channel opening require the presence of the intracellular C-terminus, which is key to the formation of the P2X<sub>7</sub>R-multiprotein complex (Ferrari *et al*, 2006).

This study was prompted by a surprising observation we made while comparing *E. coli* and P2X<sub>7</sub>R-induced activation of the NLRP3 inflammasome and IL-1 $\beta$  release in M1 polarized macrophages. We found that, though *E. coli*-induced release of IL-1 $\beta$  remained constant, ATP-evoked IL-1 $\beta$  release ceased over time in spite of continued high levels of intracellular IL-1 $\beta$  and without decreased functional P2X<sub>7</sub>R as assayed by upstream ion channel signalling. We found that unexpected changes in the polarization state of the macrophages were causing a P2X<sub>7</sub>R-specific uncoupling to the caspase-1 cascade. We therefore developed an *in vitro* model of a likely macrophage polarization gradient from extreme M1 through to extreme M2 and examined the actions of different NLRP3-inflammasome activators (ATP, *E. coli*, MTX and nigericin) over this polarization gradient, as well as in acute and chronically P2X<sub>7</sub>R -deleted M1 polarized macrophages. This study has identified a new mechanism by which extracellular ATP produces physiological inhibition of IL-1 $\beta$  release that may be key to switching a macrophage from an inducer of inflammation towards its anti-inflammatory phenotype in the resolution phase of infection or inflammation.

## Results


### Characterization of a dynamic macrophage polarity gradient

We developed an *in vitro* polarization protocol designed to rapidly mimic (over 4–8 h) a continuum of signals that are likely to drive the macrophage from the classic inflammatory M1 polarity to the anti-inflammatory M2 state (Supplementary Figure S1A available online). Macrophages from polarities close to M1 (states 1–3) were expanded and tightly fixed to substrate, formed numerous lamellar processes and elongated filopodia, with diffuse F-actin staining throughout the cytoplasm but distinctly absent from the filopodia (Figure 1A and B). Macrophages from a polarity close to M2 (state 4) presented less lamellar processes but

remained expanded and tightly fixed to the substrate, whereas the extreme M2 polarized (alternatively activated) macrophages had the same morphology as untreated cells with F-actin being tightly compacted close to the nucleus (Figure 1A and B). We quantified these changes in cell morphology by measuring total surface area over all polarizations states and found a gradual progression from state 1 through state 5 (Figure 1C,  $n = 50\text{--}70$  cells for each polarization state). We also confirmed that our protocols did, indeed, establish a molecular polarization gradient by quantitative RT-PCR (qPCR) for the classical M1 and M2 genes, TNF- $\alpha$  and mannose receptor C (MRC-1) (Gordon, 2003; Martinez *et al*, 2008); TNF- $\alpha$  gene expression was upregulated by 200-fold in M1 macrophages and this gradually decreased to near zero in extreme M2 macrophages, whereas MRC-1 gene expression gradually increased over the gradient to reach a 10-fold upregulation at extreme M2 polarization (Figure 1D).

### P2X<sub>7</sub>R, but not *E. coli*, uncouples to inflammasome activation during macrophage polarization

We found that intracellular levels of proIL-1 $\beta$  remained high in all polarization states (1–4) except, as expected (Gordon, 2003; Martinez *et al*, 2008), the alternatively activated M2 macrophages (Figure 2A and B). ATP stimulation of P2X<sub>7</sub>R in M1 activated macrophage and *E. coli* infection are both well-characterized pathways known to initiate NLRP3-inflammasome-dependent release of mature IL-1 $\beta$  (Ferrari *et al*, 2006; Mariathasan *et al*, 2006; Pétrilli *et al*, 2007). However, we found striking differences in their ability to release IL-1 $\beta$  over the polarization gradient. In agreement with numerous studies (Mariathasan *et al*, 2006; Pelegrin and Surprenant, 2006, 2007; Pétrilli *et al*, 2007), both P2X<sub>7</sub>R and *E. coli* stimulation induced the release of IL-1 $\beta$  from M1 polarized macrophages but P2X<sub>7</sub>R-induced release of IL-1 $\beta$  was significantly reduced, or absent, in macrophages of intermediate polarity (states 3, 4; Figure 2A and B). Conversely, *E. coli* induced significantly greater IL-1 $\beta$  release from these intermediately polarized macrophages (Figure 2B). Moreover, we observed a similar uncoupling of P2X<sub>7</sub>R from IL-1 $\beta$  release during traditional long-term activation of macrophages with LPS/IFN- $\gamma$  (Arend *et al*, 1989). That is, though P2X<sub>7</sub>R or *E. coli*-induced release of IL-1 $\beta$  peaked at similar times (5–10 h post activation with either LPS/IFN- $\gamma$  or *E. coli*), ATP failed to stimulate IL-1 $\beta$  release subsequently in spite of maintained high levels of intracellular IL-1 $\beta$  and in contrast to the continued release of IL-1 $\beta$  by *E. coli* (Figure 2C). Initially, we hypothesized a decrease in P2X<sub>7</sub>R expression was the most likely explanation for the failure of ATP to stimulate IL-1 $\beta$  release under these conditions, as clearly the NLRP3-inflammasome cascade known to be activated by *E. coli* (Pétrilli *et al*, 2007) was not affected. However, we could not attribute this loss of P2X<sub>7</sub>R-mediated release of IL-1 $\beta$  to loss of functional receptors because (i) P2X<sub>7</sub>R gene expression was actually downregulated in M1 macrophages and did not change from states 1 to 3, then increased in states 4 and 5 (Figure 1D); (ii) P2X<sub>7</sub>R protein localization remained constant through all polarization states, in particular the P2X<sub>7</sub>R protein showed a similar punctate expression along the cell (Figure 2D); (iii) assays for upstream signalling of P2X<sub>7</sub>R (calcium flux and dye-uptake) (Pelegrin and Surprenant, 2006) did not change over the polarity gradient (Figure 2E and F). Macrophages obtained




**Figure 1** Functional macrophage plasticity during a polarization gradient. (A, B) Deconvolved images of peritoneal macrophages during polarization gradient (conditions from 1 to 5, see ‘Materials and methods’) immunostained for mouse macrophage surface marker F4/80 (A) or labelled with Texas Red-phalloidin to reveal F-actin cytoskeleton (B). Images are representative of three independent experiments; bar = 5  $\mu\text{m}$ . (C) Cellular area measure from peritoneal macrophage during polarization gradient;  $n = 50\text{--}70$  cells from three independent experiments. Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges; \*\* $P < 0.001$ . (D) Real-time quantitative RT-PCR for classical M1 (TNF- $\alpha$ ) and M2 (mannose receptor C type 1, MRC-1) genes and P2X<sub>7</sub>R gene during macrophage polarization gradient. Data are average of triplicate reactions and representative of three independent experiments.

from P2X<sub>7</sub>R gene-deleted mice were subjected to the same polarization gradient protocols and served as controls; in these macrophages no anti-P2X<sub>7</sub>R antibody staining was present (data not shown) and no ATP-mediated calcium flux or dye-uptake occurred in M1 macrophages (Figure 2E and F) or in M2 macrophages (data not shown).

#### From positive to negative regulation of IL-1 $\beta$ release by ATP during macrophage polarization

We next compared inflammasome activation profiles induced by ATP and by two toxins, MTX and nigericin, which activate the NLRP3-inflammasome with similar kinetics and mechanisms to P2X<sub>7</sub>R (Mariathasan *et al.*, 2006; Pelegrin and Surprenant, 2007) (Supplementary Figure S1B). IL-1 $\beta$  ELISA assays (which recognize pro and mature forms of the cytokine) showed that ATP-induced IL-1 $\beta$  release was reduced by 50–80% in state 3 intermediate polarized macrophages compared with M1 polarized cells (Figures 2B and 3A), whereas MTX-


induced IL-1 $\beta$  release was the same in macrophages from either polarity state or similar to levels of ATP-induced release from M1 macrophages (Figure 3A). When ATP and MTX were co-applied, IL-1 $\beta$  release was increased in M1 macrophages to the same extent as in the presence of either compound alone (Figure 3A). However, co-application of MTX and ATP to state 3 polarized macrophages resulted in a 50% reduction of IL-1 $\beta$  release (Figure 3A). Western blots showed typical release of mature IL-1 $\beta$  from M1 macrophage in response to ATP, MTX or a combination of MTX and ATP whereas in state 3 polarized macrophages; mature IL-1 $\beta$  was detected in response to MTX but not ATP stimulation and co-application significantly decreased release of mature IL-1 $\beta$  (Supplementary Figure S2A). Strikingly, ATP completely prevented MTX-induced release of IL-1 $\beta$  in M1 polarized macrophages after acute blockade of P2X<sub>7</sub>R with the P2X<sub>7</sub>R-selective antagonist, A740003 (Honore *et al.*, 2006) (Figure 3B; Supplementary Figure S2B). ATP similarly inhibited both MTX and nigericin-induced release of IL-1 $\beta$  from M1 polar-



**Figure 2** P2X<sub>7</sub>R signalling during macrophage polarization gradient. (A) IL-1 $\beta$  and  $\beta$ -actin immunoblot of murine peritoneal macrophage lysates and supernatants during a polarization gradient from M1 towards M2 (conditions from 1 to 5, see 'Materials and methods') in the presence or absence of 5 mM ATP (15 min). ATP does not release IL-1 $\beta$  in states 3 and 4 despite high levels of intracellular pro-IL-1 $\beta$ ; blots are representative of three independent experiments. (B, C) ELISA comparing intracellular production and release of IL-1 $\beta$  by mouse peritoneal macrophages induced by ATP (5 mM for 15 min) or *E. coli* (4 h) after 4 h of polarization to M1 (1, red: LPS and IFN- $\gamma$ ), to M2 (5, blue: IL-4) or to intermediate polarization state (3, green: LPS, IFN- $\gamma$  and IL-4) (B) or after priming for 0–24 h with LPS and IFN- $\gamma$  (C);  $n = 3$  independent cultures for each condition, \* $P = 0.0483$ , \*\* $P = 0.0014$ . (D) Deconvolved images of M1 (left panel) or M2 (right panel) polarized peritoneal macrophages immunostained for F4/80 (red) and for P2X<sub>7</sub>R (green). Bar, 5  $\mu$ m. (E) Fura2 fluorescence ratio recorded from peritoneal macrophages isolated from P2X<sub>7</sub>R<sup>+/+</sup> or P2X<sub>7</sub>R<sup>-/-</sup> mice polarized to M1, M2 or to an intermediate polarization state. P2X<sub>7</sub>R receptors were activated with ATP (1 mM, arrow) resulting in typical sustained intracellular calcium increase. Traces are the average of 4–6 independent cultures and representative of three independent experiments. (F) Kinetics of dye-uptake (ethidium bromide fluorescence) in peritoneal macrophages isolated from P2X<sub>7</sub>R<sup>+/+</sup> or P2X<sub>7</sub>R<sup>-/-</sup> mice polarized to M1, M2 or to an intermediate polarization state in response to 5 mM ATP (arrow),  $n = 3$  independent experiments in each case.

ized macrophages obtained from P2X<sub>7</sub>R-deleted mice (Figure 3C; Supplementary Figure S2C). ATP also inhibited caspase-1 activation (Figure 3C, lower panels) and release of the inflammasome adaptor protein, Apoptosis-associated Speck-like protein containing a C-terminal caspase-activating recruiting domain (ASC, Figure 3D) induced by either MTX or nigericin in M1 polarized P2X<sub>7</sub>R<sup>-/-</sup> macrophages.

Re-introduction of P2X<sub>7</sub>R into P2X<sub>7</sub>R<sup>-/-</sup> macrophages through adenoviral delivery reconstituted all features of ATP-mediated IL-1 $\beta$  release and caspase-1 activation from M1 polarized macrophages (Supplementary Figure S1D and E). ATP also failed to induce caspase-1 activation in M2 wild-type polarized macrophages (Figure 3E), although upstream signalling through P2X<sub>7</sub>R (calcium flux, dye-uptake) was not



**Figure 3** Switch from positive to negative regulation of IL-1 $\beta$  release by ATP during macrophage polarization gradient. (A) IL-1 $\beta$  release by untreated (U), M1 polarized (1: LPS and IFN- $\gamma$ ) or intermediate polarized (3: LPS, IFN- $\gamma$  and IL-4) mouse peritoneal macrophages activated for 15 min with ATP (5 mM), maitotoxin (MTX, 0.2 nM) or a combination of ATP and MTX detected by ELISA;  $n = 3$  independent cultures for ELISA; \* $P = 0.0121$ ; \*\* $P = 0.0013$ . (B) IL-1 $\beta$  release by M1 polarized mouse peritoneal macrophages induced by 15 min of ATP (5 mM), MTX (0.2 nM) or a combination of ATP and MTX in the presence of absence of P2X $_7$ R antagonist A740003 (10  $\mu$ M, 5 min before ATP/MTX) detected by immunoblot; blots are representative of three independent experiments. (C) Immunoblots for intracellular IL-1 $\beta$  (top panels), released IL-1 $\beta$  (middle panels) and released active caspase-1 (p10 subunit, bottom panels) in M1 polarized peritoneal macrophages from P2X $_7$ R $^{+/+}$  or P2X $_7$ R $^{-/-}$  mice stimulated for 15 min with ATP (5 mM), maitotoxin (MTX, 0.2 nM), nigericin (5  $\mu$ M) or a combination of ATP and MTX or ATP and nigericin; blots are representative of 3–13 independent experiments. (D) Immunoblots for intracellular (top panel) and released (bottom panel) ASC in M1 polarized peritoneal macrophages from P2X $_7$ R $^{-/-}$  mice stimulated during 15 min with ATP (5 mM), MTX (0.2 nM) or a combination of ATP and MTX; blots are representative of two independent experiments. (E) Representative traces for caspase-1 activity in M1 or M2 polarized peritoneal macrophages from P2X $_7$ R $^{+/+}$  or P2X $_7$ R $^{-/-}$  mice monitored over 30 min with the fluorescent probe TMR-YVADAC(AD) after stimulation with 5 mM ATP (arrow). Traces are the average of four independent cultures and are representative of two independent experiments. (F) P2X $_7$ R $^{-/-}$  M1 polarized peritoneal macrophages were challenged with *E. coli* for 1 h in the absence or presence of 5 mM ATP and further incubated for 4 h, IL-1 $\beta$  was detected by immunoblot. Blots are representative of three independent experiments.


significantly different than observed in M1 macrophages. Taken together, these results show that the inhibitory action of ATP on these macrophages was due solely to lack of P2X $_7$ R downstream signalling and not to alterations in the NLRP3 inflammasome itself. ATP was equally able to inhibit IL-1 $\beta$  release from the *in vitro* *E. coli* model of infection and slow NLRP3 activation (e.g. Figure 2C; Supplementary Figure S1C) in M1 polarized macrophages from P2X $_7$ R $^{-/-}$  macrophages (Figure 3F; Supplementary Figure S2D). This inhibition was not because of alterations in binding or phagocytosis of the bacteria by these macrophages in the presence of ATP (Supplementary Figure S2E).

**Negative regulation of IL-1 $\beta$  by ATP is not through purinoreceptors but is due to pyrophosphate actions**

We expected the inhibitory actions of ATP, which occurred during macrophage polarization from M1 towards M2 states

or which were revealed by acute (selective P2X $_7$ R antagonist) or chronic (P2X $_7$ R $^{-/-}$  macrophage) blockade of P2X $_7$ R, to result from activation of one, or more, purinergic P2X, P2Y or adenosine receptors. However, results shown in Figure 4, Supplementary Figure S3A, and E quickly ruled out involvement of any of these receptors in the inhibition of IL-1 $\beta$  release by ATP. We used M1 polarized macrophages from P2X $_7$ R $^{-/-}$  mice (Figure 4A–E) or from wild-type mice in the presence of A740003 (data not shown) and examined the actions of ATP and other purines on MTX-induced IL-1 $\beta$  release and caspase-1 activation. First, the ATP concentration–inhibition curve was 20–100-fold to the right of all known purine and adenosine receptors except for P2X $_7$ R; indeed, the IC $_{50}$  value for ATP inhibition of MTX-induced IL-1 $\beta$  release in P2X $_7$ R-depleted macrophage (1.54  $\pm$  0.03 mM,  $n = 3$ ) was not significantly different from the ATP EC $_{50}$  value to induce release of IL-1 $\beta$  from wild-type M1 macrophages





**Figure 4** Negative regulation of IL-1 $\beta$  release by ATP is not because of a purine receptor but to pyrophosphate action. (A–C) Inhibition of MTX (0.2 nM, 15 min) induced IL-1 $\beta$  release in M1 polarized peritoneal macrophages from P2X<sub>7</sub>R<sup>-/-</sup> with the indicated concentrations of ATP (A) or 5 mM of ATP, ADP, AMP, adenosine (AD) or 0.1 or 5 mM of pyrophosphate (PPi) (B, C); immunoblots for intracellular IL-1 $\beta$  (top panels), released IL-1 $\beta$  (middle panels) or released active caspase-1 (p10 subunit, bottom panels) (A, B) or ELISA for released IL-1 $\beta$  (C). (D) Immunoblots for intracellular IL-1 $\beta$  (top panel) or released IL-1 $\beta$  (bottom panel) in M1 polarized peritoneal macrophages from P2X<sub>7</sub>R<sup>-/-</sup> mice stimulated for 15 min with MTX (0.2 nM) and 5 mM of ATP, PPi, inorganic phosphate (Pi) or 1 mM clodronate. (E) Concentration–inhibition curves (solid symbols) of IL-1 $\beta$  release in M1 polarized peritoneal macrophages from P2X<sub>7</sub>R<sup>-/-</sup> mice stimulated with MTX (0.2 nM, 15 min) in the presence or absence of different concentrations of ATP (triangles), PPi (circles) or clodronate (squares). Concentration–response curve (open diamonds) of IL-1 $\beta$  release in M1 polarized peritoneal macrophages from P2X<sub>7</sub>R<sup>+/+</sup> mice stimulated with different concentrations of ATP (15 min);  $n = 3$  for each point. (F) Immunoblots for released IL-1 $\beta$  of M1 polarized (1: LPS and IFN- $\gamma$ ) or intermediate polarized (3: LPS, IFN- $\gamma$  and IL-4) peritoneal macrophages from P2X<sub>7</sub>R<sup>+/+</sup> mice stimulated for 15 min with MTX (0.2 nM) or ATP (5 mM) in the presence or absence of PPi (5 mM), clodronate (1 mM) or Pi (5 mM).  $n = 3$  independent cultures for ELISA and blots are representative of two to three independent experiments.

(1.65  $\pm$  0.02 mM,  $n = 3$ ) (Figure 4A and E). Second, significant inhibition was observed with ATP > ADP  $\gg$  AMP but not with adenosine (Figure 4B and C). Third, the non-selective P2X/P2Y inhibitor, suramin and the non-selective P2X antagonist, PPADS, did not alter the inhibition by ATP of the nigericin-induced IL-1 $\beta$  in P2X<sub>7</sub>R-deficient M1 macrophages (Supplementary Figure S3A). Most directly, pyrophosphate (PPi, Figure 4B–E) and triphosphate (Supplementary Figure S3C) but not monophosphate (Figure 4D) inhibited IL-1 $\beta$  release and caspase-1 activation more potently than ATP, with an IC<sub>50</sub> value for PPi of 1.03  $\pm$  0.05 mM ( $n = 3$ ). The non-hydrolysable bisphosphonate, clodronate (Supplementary Figure S3D), exerted the same inhibition and was 3–5-fold more potent than PPi or ATP, with an IC<sub>50</sub> value of 0.43  $\pm$  0.14 mM. (Figure 4D and E). Both PPi and clodronate were effective to inhibit MTX-mediated IL-1 $\beta$  release from wild-type M1 or M1/M2 intermediate polarized macrophages but neither inhibited ATP-mediated release from these cells

(Figure 4F). Finally, in HEK cells heterologously expressing P2X receptors or endogenously expressing P2Y receptors, neither PPi (5 mM) nor clodronate (1 mM) alone had any effect on membrane currents (data not shown) or cytosolic calcium transients, and nor did they significantly alter the ATP-evoked responses in these cells (Supplementary Figure S3E).

Clodronate and other bisphosphonates, when encapsulated in liposomes, have been a widely used mechanism to selectively destroy macrophages (van Rooijen and Sanders, 1994) because macrophages phagocytose the liposomes; lysosomal phospholipases break down the liposomes and the resulting free intracellular bisphosphonates initiate apoptosis (van Rooijen and Sanders, 1997). Free bisphosphonates have not been found to accumulate intracellularly (Pennanen *et al*, 1995). Nevertheless, we asked whether the application of clodronate as used in our experiments (up to 30 min applications) may have toxic actions on macrophage that

would explain the inhibition of IL-1 $\beta$  by measuring LDH release from all experiments (Supplementary Figure S3B). No increase in LDH release over basal conditions was observed and in all cases LDH release was <1–3% of total LDH levels ( $n=10$ –14). This result and the observation that clodronate alone did not alter intracellular calcium levels (Supplementary Figure S3E) provide conclusive evidence against a toxic action of clodronate on these macrophages.

#### **ATP differentially regulates actin polymerization and inflammasome localization during macrophage polarization gradient**


P2X<sub>7</sub>R and MTX stimulation of M1 polarized macrophages are associated with rapid and dramatic cytoskeletal re-arrangements (Pfeiffer *et al*, 2004; Verhoef *et al*, 2004). We noticed a striking difference in the actions of ATP on cell morphology over the M1–M2 polarization gradient, and therefore asked whether this may be associated with their actions to inhibit inflammasome activation. We examined F-actin distribution before and 5 min after the addition of ATP (5 mM), MTX (0.2 nM) or ATP with MTX in M1 polarized wild type and P2X<sub>7</sub>R<sup>-/-</sup> macrophage, in intermediate state 3 polarized wild-type macrophage and in M1 polarized wild-type macrophage treated with A740003 (Figure 5A). ATP induced intense F-actin distribution to only one side of the cell with extensive ramifications radiating outward over the other side; MTX induced an equally intense but uniform F-actin localization around the entire cell whereas co-application produced a randomly radiating network of F-actin (Figure 5A, panels i–iv; Supplementary Figure S4C). In striking contrast, ATP induced an intense intracellular clustering of F-actin in macrophage from intermediate state 3 polarization as well as from acute and chronic P2X<sub>7</sub>R-depleted macrophages (Figure 5A, panels vi, x, xiv), whereas MTX produced essentially the same F-actin pattern as observed in M1 polarized wild-type macrophages (Figure 5A, panels vii, xi, xv). Co-application of ATP and MTX to intermediate state 3 polarized macrophages produced both intracellular F-actin clustering and radiating F-actin ramifications (Figure 5A, panel viii) but co-application to P2X<sub>7</sub>R-depleted M1 macrophages produced the same pattern of intense intracellular clustering as seen with ATP alone in these macrophages (Figure 5A, panel xii; Supplementary Figure S4C). PPI and clodronate induced a similar pattern of intracellular clustering of F-actin when co-applied with MTX in P2X<sub>7</sub>R-depleted macrophages and prevented polymerization of F-actin to the cell edge (Supplementary Figure S4A and C).

To investigate whether the dynamics of F-actin polymerization were important for the inhibition of inflammasome activation by ATP and PPI, we treated M1 polarized P2X<sub>7</sub>R<sup>-/-</sup> macrophages with cytochalasin B (CB) to disrupt coordinated actin cytoskeleton assembly. In agreement with earlier studies demonstrating that actin-based cytoskeletal pathways are not directly involved with IL-1 $\beta$  processing and release (Hornung *et al*, 2008), we found that CB itself did not induce IL-1 $\beta$  release nor did it alter MTX-induced release (Figure 5B and C). However, CB partially reversed (by 30–50%) the blockade of MTX-induced IL-1 $\beta$  by ATP and PPI (Figure 5B and C) and prevented intracellular actin clustering (Supplementary Figure S4B). To gain further insight into potential mechanisms underlying this earlier undetected involvement of the actin cytoskeleton in NLRP3-inflammasome

inhibition, we used a caspase-1-specific fluorescent probe to directly identify active caspase-1 within the macrophage. No active caspase-1 was detected in unstimulated M1 polarized macrophages from P2X<sub>7</sub>R<sup>+/+</sup> (Figure 6A, upper panels) or P2X<sub>7</sub>R<sup>-/-</sup> mice (Figure 6B, left panel). Stimulation of M1 polarized wild-type macrophages with ATP, or P2X<sub>7</sub>R<sup>-/-</sup> macrophages with MTX, for 5 min led to robust caspase-1 activation in discrete intracellular aggregates that are likely to represent sites of active inflammasome complexes (Figure 6A, lower panels and B, middle panel). Several of these active caspase-1 aggregates were observed within the actin barrier at the edge of the cell (Figure 6A and B, arrows), suggestive of potential caspase-1/IL-1 $\beta$  release sites. ASC immunostaining of unstimulated M1 macrophages showed a uniform cytosolic distribution (Figure 6A, upper middle panel), whereas ASC formed clusters after ATP stimulation, many of which co-localized with active caspase-1 (Figure 6A, arrowheads), confirming their status as an activated inflammasome complex. However, we also observed many ASC-only and caspase-1-only aggregates on ATP stimulation, which may indicate heterogeneous subpopulations of inflammasome-like complexes (Figure 6A, lower middle panel). We did not observe any co-localization of active caspase-1 with the lysosomal marker, cathepsin L (Figure 6A, right panels), which is in agreement with recent studies showing that the early release of IL- $\beta$  does not occur through lysosomal secretory pathways (Brough and Rothwell, 2007).

#### **Modulation of redox signalling by ATP and PPI during macrophage polarization**

We hypothesized that the inhibition of IL-1 $\beta$  processing and release by ATP and PPI that was not reversed by treatment with CB (i.e. the actin-independent inhibition) may result from reduced ROS production because P2X<sub>7</sub>R stimulation of M1 polarized macrophages is known to increase ROS production and is associated with NLRP3-inflammasome activation (Dostert *et al*, 2008; Hewinson *et al*, 2008) (Supplementary Figure S4D) and ATP, PPI and bisphosphonates may act directly or indirectly as oxygen radical scavengers (Serretti *et al*, 1993; Kachur *et al*, 1997; Dombrecht *et al*, 2006). Both ATP and MTX induced similar rapid (within 2–3 min) increases in ROS production from M1 polarized macrophages (Figure 7A and E) but in M2 polarized macrophages the enhanced ROS production was significantly delayed (no significant increase occurred before 8–10 min) and reduced (Figure 7B and E). MTX similarly increased ROS production from M1 polarized P2X<sub>7</sub>R<sup>-/-</sup> macrophages (Figure 7C and E), but MTX-induced ROS production in these cells was prevented by ATP, PPI and clodronate with IC<sub>50</sub> values not significantly different from those obtained for inhibition of IL-1 $\beta$  release (Figure 7C–E), and similar to the ROS scavenger *N*-acetyl cysteine (Figure 7E). Similarly, PPI and clodronate were able to block MTX-induced ROS production in M1 wild-type macrophages, but fail to block P2X<sub>7</sub>R-induced ROS production from the same cells (Figure 7E), this could explain the underlying mechanism for the differential activation of the inflammasome by ATP and MTX observed between M1 and intermediate polarized macrophages (Figures 3A and 4F). Finally, MTX stimulation of ROS production and its inhibition by ATP and PPI were not significantly altered by treatment with cytochalasin B (Figure 7F).




**Figure 5** ATP differentially regulates actin polymerization during macrophage polarity gradient. **(A)** Deconvolved images of F-actin cytoskeleton labelled with Texas Red-phalloidin in peritoneal macrophages isolated from P2X<sub>7</sub>R<sup>+/+</sup> or P2X<sub>7</sub>R<sup>-/-</sup> mice after differentiation to M1 or to intermediate state 3 polarization state, unstimulated or stimulated for 5 min with ATP (5 mM), MTX (0.2 nM) or a combination of ATP and MTX, in the presence or absence of A740003 (10 μM, 5 min before ATP). Bar, 5 μm. Images are representative of three independent experiments. **(B, C)** M1 polarized peritoneal macrophages isolated from P2X<sub>7</sub>R<sup>-/-</sup> mice were treated with cytochalasin B (CB; 2.5 μg/ml, 5 min before MTX) and stimulated for 15 min with MTX (0.2 nM) or a combination of MTX and ATP (5 mM) or PPI (3 mM), and IL-1β release was detected by immunoblots (B) or by ELISA (C); n = 3 independent cultures for ELISA and representative of two independent experiments, blots are representative of two independent experiments.

## Discussion

The concept of monocytes/macrophages existing in functionally distinct phenotypes from pro- to anti-inflammatory states has been well established by detailed studies on M1 (classically activated) and M2 (alternatively activated) macrophages (Gordon, 2003; Scotton *et al*, 2005; Martinez *et al*,

2006, 2008). However, only recently it has begun to be appreciated that macrophages are able to reversibly and dynamically switch from one activation state to the other (Stout and Suttles, 2004; Porcheray *et al*, 2005; Gratchev *et al*, 2006). Here, we have used a polarization gradient of cytokines and endotoxin to rapidly generate a 5-stage *in vitro* model of macrophage polarization from M1 through M2. In





**Figure 6** Cellular dynamics and localization of the inflammasome. (A) Deconvolved images of P2X<sub>7</sub>R<sup>+/+</sup> M1 polarized peritoneal macrophages stained for active caspase-1 (green) and F-actin cytoskeleton (red, left panels), ASC (red, middle panels) or cathepsin L (red, right panels), before (top panels) or after (bottom panels) stimulation with ATP (5 mM, 5 min). Arrows show active caspase-1 crossing actin barrier and presumably being released; co-localization of active caspase-1 with ASC (arrowheads) indicating active inflammasomes; note no colocalization between active caspase-1 and lysosomal marker cathepsin L. (B) M1 polarized peritoneal macrophages isolated from P2X<sub>7</sub>R<sup>-/-</sup> mice labelled for active caspase-1 (green) and F-actin cytoskeleton with Texas Red-phalloidin (red) stimulated for 5 min with MTX (0.2 nM) alone or in combination with ATP (5 mM). Bar, 5 μm. Images are representative of two independent experiments.

states 1–4, intracellular IL-1β remained high and all stimuli except ATP continued to activate the inflammasome and release IL-1β. In intermediate polarization states, as well as in P2X<sub>7</sub>R-deficient macrophages, ATP no longer signalled to caspase-1 activation; rather, ATP now acted through its diphosphate and/or triphosphate chains independently of any other purine receptor to block activation of the NLRP3 inflammasome by other activators. This was accomplished by two independent mechanisms: a direct reduction in ROS production and a rapid trapping of the inflammasome complex because of dramatic intracellular clustering of the actin cytoskeleton. Our results suggest this uncoupling of P2X<sub>7</sub>R from caspase-1 activation may prove to be a key trigger in the switch from a pro-inflammatory macrophage towards its alternative functions in the resolution of inflammation. Moreover, we have identified a new cellular mechanism by which the inflammasome can be inhibited through physiological alterations in the cytoskeleton.

The characteristics of P2X<sub>7</sub>R-induced release of IL-1β from M1 activated macrophages are well established: intracellular pro-caspase-1 is rapidly cleaved and mature IL-1β, as well as caspase-1 and other inflammasome components (e.g. ASC) are released within minutes (2–10 min) after receptor stimulation (Mariathasan *et al.*, 2004, 2006; Ferrari *et al.*, 2006; Pelegrin and Surprenant, 2006). In this study we compared these established properties of P2X<sub>7</sub>R activation in M1 macrophages with those of macrophages exposed to a gradient of M1–M2 activation. We have focused on the intermediate polarization state (state 3) in wild-type mouse macrophages because it provides us with a representation of a macrophage on the cusp between M1 and M2 phenotypes. In state 3, intermediate polarized macrophages intracellular levels of pro-IL-1β were similar to M1 macrophages, and P2X<sub>7</sub>R mRNA levels, protein levels and protein localization patterns showed no clear differences from M1 macrophages. Initial upstream signalling events, which occur in the seconds to




(suramin and PPADS) did not alter the inhibition by ATP observed in P2X<sub>7</sub>R-deficient macrophages and, unequivocally, because pyrophosphates (tri and di, but not mono, phosphates) as well as the non-hydrolysable bisphosphonate, clodronate, inhibited caspase-1 activation and IL-1 $\beta$  with potency order of clodronate > triphosphate  $\approx$  diphosphate > ATP  $\gg$  ADP, suggesting that the diphosphate group resident in ADP could partially block inflammasome without involvement of PPi metabolism. It is tempting to speculate that ecto-nucleotidases may play a critical role in the switch of a macrophage from an M1 to an M2 state during inflammatory resolution but future studies of expression levels and activities of the large family of these molecules (Zimmermann, 2000) are likely to provide insight into whether specific ecto-nucleotidases may have a critical function in the switch of a macrophage from an M1 to an M2 state during inflammatory resolution. In any event, our results show that when P2X<sub>7</sub>Rs are fully functional, that is when they couple to inflammasome activation in M1 macrophages, the actions of ATP are solely stimulatory on IL-1 $\beta$  release. That is, neither PPi nor clodronate inhibited ATP-mediated IL- $\beta$  release from M1 macrophages nor even from state 3 intermediate polarized macrophages in which the P2X<sub>7</sub>R-specific IL-1 $\beta$  release was still present although at a much reduced level, while they effectively blocked MTX- and *E. coli*-induced inflammasome activation. These results further support our suggestion that a specific uncoupling of otherwise functional P2X<sub>7</sub>Rs from the caspase-1 cascade is the key event in the switch of ATP from inducing (through P2X<sub>7</sub>R) to inhibiting (through PPP/PPi) IL-1 $\beta$  release (Figure 8). Recent pharmacological studies have shown that ROS production in M1 macrophages is a critical step for activation of the NLRP3 inflammasome in response to ATP, toxins or crystals (Dostert *et al*, 2008; Hewinson *et al*, 2008) and P2X<sub>7</sub>R activation recruits to the plasma membrane and activates NADPH oxidase complex (Hewinson *et al*, 2008). However, a recent study has not found genetic support for the role of ROS in NLRP3-inflammasome activation (Hornung

*et al*, 2008). Here, we found that in M2 macrophages P2X<sub>7</sub>R activation induces only a weak ROS response that may be owing to a specific uncoupling from recruitment of the NADPH oxidase complex without alterations in P2X<sub>7</sub>R upstream signalling, correlating with the low level of NLRP3 activation and IL-1 $\beta$  release found in intermediate polarized macrophages after ATP/P2X<sub>7</sub>R stimulation.

By imaging individual macrophages using a caspase-1-specific fluorescent probe and co-labelling for actin or ASC as an integral component in the inflammasome complex, we found that P2X<sub>7</sub>R activation in M1 macrophages not only induced rapid actin cytoskeletal rearrangements along a spatial gradient but also rapid formation of active caspase-1/ASC aggregates, which we interpret as likely sites of functionally active inflammasomes. Several of these aggregates tightly abutted the external surface of actin filaments outlining the plasma membrane, suggesting potential sites of release. In striking contrast, ATP applied to P2X<sub>7</sub>R-depleted M1 macrophages, or to state 3 intermediate polarized macrophages, produced a rapid and intense intracellular clustering of actin filaments. A similar pattern of intracellular clustering of actin was observed when ATP, pyrophosphate or clodronate were co-applied with MTX to these macrophages with little or no activated caspase-1 fluorescence signals. Cytochalasin B blocked this intracellular aggregation of actin and reversed by 30–50% the inhibition of release observed in the presence of MTX plus ATP or pyrophosphate. Thus, we have identified intracellular clustering of actin filaments as a novel mechanism for inhibition of inflammasome activation (Figure 8).

This study has direct and immediate clinical and physiological relevance. Clodronate and other bisphosphonates have been in clinical use for decades, primarily for the treatment of osteoarthritis and other inflammatory or metastatic bone diseases (Maksymowych, 2002; Russell *et al*, 2008). Their primary mechanism of action is generally considered to be one of effective chelation of calcium crystal deposits on bone mineral surfaces, resulting in inhibition of osteoclast



**Figure 8** Proposed model for inflammasome regulation by extracellular ATP during macrophage polarization gradient. In M1 polarized macrophages ATP acting through P2X<sub>7</sub>R is linked with an increase production of ROS, actin polymerization to the edge of the cell, activation of the NLRP3 inflammasome/caspase-1 and rapid release of the pro-inflammatory mature IL-1 $\beta$  cytokine. However, during the resolving phase of the inflammation M1 macrophages switch their phenotype towards M2 and now P2X<sub>7</sub>R uncouples to both ROS production and the NLRP3-inflammasome/caspase-1 pathway although it remains functional in terms of its ion channel activity. Under these conditions (intermediate state 3) the PPi group of ATP acts to further inhibit ROS and induces an intracellular clustering of actin that blocks the inflammasome/activation of caspase-1 and the release of mature IL-1 $\beta$  to enhance the resolving phase of the inflammation. The PPi may result from ATP metabolism by ecto-nucleotidases or may act by phosphate chains remaining attached to the nucleotide molecule.

apoptosis and bone resorption (Russell *et al.*, 2008). Conversely, several studies have provided evidence that they may also exert an anti-inflammatory action in bone and immune cells independent of their calcium chelation properties (Pennanen *et al.*, 1995; Maksymowych, 2002). The pyrophosphate actions to inhibit IL-1 $\beta$  release identified in this study may underlie these anti-inflammatory actions of bisphosphonates. A novel, highly selective and potent P2X<sub>7</sub>R antagonist, AZ9056, is currently in clinical trials for rheumatoid arthritis (McInnes *et al.*, 2007). Studies to date point to the primary mechanism of action of such P2X<sub>7</sub>R antagonists as being through inhibition of IL-1 $\beta$  release (Labasi *et al.*, 2002; Pelegrin, 2008). Our present work continues to support this conclusion but now raises the possibility that a secondary effect of P2X<sub>7</sub>R inhibition is to further inhibit IL-1 $\beta$  release evoked by other activators by allowing pyrophosphates—either through extracellular ATP metabolism or directly through the phosphate chains of the intact nucleotides—to directly prevent inflammasome activation by other bacterial or endogenous inflammatory mediators through inhibition of ROS production and by intracellular trapping of the inflammasome complex. Clinical investigations into the potential of co-therapy with P2X<sub>7</sub>R antagonists and bisphosphonates in chronic inflammatory diseases may prove fruitful.

## Materials and methods

### Cells and reagents

Key reagents and their sources: *E. coli* LPS O55:B5, ATP, ADP, AMP, adenosine, PPI, triphosphates, *N*-acetyl cysteine,  $\alpha$ -tocopherol, nigericin (Sigma); MTX (Alexis); clodronate, caspase-1 substrate (N<sup>3</sup>-5-tetramethylrhodaminyl-YVADAC(S-acrylodan)-OH), cytochalasin B (Calbiochem); IFN- $\gamma$ , IL-4 and IL-1 $\beta$  (PeproTech). *E. coli* DH5 $\alpha$  strain, DAPI, phalloidin-Texas Red and OxyBURST H<sub>2</sub>HFF-BSA (Invitrogen). Abs for ELISAs and cathepsin L were from R&D, for P2X<sub>7</sub>R from Alamone Laboratories, caspase-1 p10 rabbit polyclonal and  $\beta$ -actin from Santa Cruz Biotechnology, ASC from Alexis, IL-1 $\beta$  mAb from the Biological Resources Branch, National Cancer Institute. All HRP-conjugated secondary Abs were from DAKO Cytomation. A740003 P2X<sub>7</sub>R antagonist was synthesized by ArtMolecule.

C57BL/6J (P2X<sub>7</sub>R<sup>+/+</sup>) and P2X<sub>7</sub>R-deficient (P2X<sub>7</sub>R<sup>-/-</sup>) mice in C57BL/6J background were used (Chessell *et al.*, 2005). All experiments were performed under the Animals (Scientific Procedures) Act 1986. Peritoneal macrophages were obtained as described earlier (Pelegrin and Surprenant, 2006). Briefly, the peritoneal cavity was gently lavaged with phosphate-buffered saline (PBS, Invitrogen). The recovered buffer from two to three mice was pooled, cells were collected by centrifugation (250g, 5 min) and plated on coverslips, or in 12-well plates at a density of 10<sup>6</sup> cell/well, or in 24-well plates at a density of 0.5  $\times$  10<sup>6</sup> cell/well, or in 96-well plates black with clear bottom at a density of 1.5  $\times$  10<sup>6</sup> cell/well in RPMI 1640 media (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 100 units/ml penicillin and 100  $\mu$ g/ml streptomycin (Invitrogen). The macrophages were allowed to adhere overnight (37°C, 5% CO<sub>2</sub>) and washed with fresh medium to remove unattached cells before use.

### Cell culture and stimulation

Macrophages plated on 12-well plates were primed with fresh medium supplemented with different stimuli to obtain a gradient of polarity phenotypes (Supplementary Figure S1A). For clarity, the different polarity phenotypes have been represented in the figures and in the text with a number, a colour and a shape. LPS (1  $\mu$ g/ml) and IFN- $\gamma$  (20 ng/ml) for 4 h were used to differentiate to M1 phenotype (polarity state 1, square, red). IL-4 (20 ng/ml) was used for 4 h to differentiate to M2 phenotype (polarity state 5, round, blue). A combination of LPS/IFN- $\gamma$ /IL-4 for 4 h was used to differentiate an M1/M2 intermediate macrophage polarization phenotype (polarity state 3, diamond, green). To study the polarity

changes and to achieve intermediate polarity states, cells were stimulated first for 4 h with IL-4, washed and then stimulated for further 4 h with LPS/IFN- $\gamma$  (polarity state 2, star, pink); or stimulated first for 4 h with LPS/IFN- $\gamma$ , washed and then stimulated for further 4 h with IL-4 (polarity state 4, triangle, yellow). Macrophages were stimulated for 15 min with agonists as described earlier (Pelegrin and Surprenant, 2007). Alternatively, to examine the blocking of IL-1 $\beta$  release, macrophages were incubated with 0.01–5 mM of ATP, PPI, triphosphate or clodronate or with 5 mM of ADP, AMP, AD or Pi or with 20 mM *N*-acetyl cysteine or 10  $\mu$ M  $\alpha$ -tocopherol together with MTX (0.2 nM). *E. coli* stimulation was performed as described earlier (Pétrilli *et al.*, 2007). Macrophages were stimulated either with LPS/IFN- $\gamma$  (polarity state 1), IL-4 (polarity state 5) or with a combination of LPS/IFN- $\gamma$ /IL-4 (polarity state 3) for 2 h, washed in Optimem and challenged with *E. coli* for 1 h in the presence or absence of ATP (0.1–5 mM); the cells were then washed and placed in Optimem complemented with 100 units/ml penicillin and 100  $\mu$ g/ml streptomycin for further 4 h.

### Western blot, ELISAs, intracellular calcium and dye-uptake assays

Detailed methods used for western blot analysis, ELISAs, Fura2 calcium imaging and ethidium bromide uptake have been described earlier (Pelegrin and Surprenant, 2006). Blots were analysed by densitometry measurements using NIH ImageJ software (<http://rsb.info.nih.gov/ij/>).

### Immunocytochemistry and microscopy

Macrophages stimulated on coverslips were washed twice with PBS, fixed with 4% formaldehyde for 30 min at room temperature, and then washed three times with PBS. Cells were blocked with 3% bovine serum albumin and permeabilized with 0.1% triton X-100 in PBS for 30 min at room temperature before incubating with rat anti-mouse F4/80 antibody (1:500), rabbit anti-P2X<sub>7</sub>R (1:500), rabbit anti-ASC (1:250) or with goat anti-cathepsin L (1:250) for 18–20 h at 4°C or for 2 h at room temperature. Cells were washed and incubated with appropriate FITC-, TRITC- or Cy3-conjugated secondary antibody (1:200) for 2 h at room temperature, then rinsed in PBS and incubated for 15 min with 300 nM of DAPI and in some experiments with phalloidin-Texas Red (1:100). To stain for active caspase-1, macrophages were activated with 5 mM ATP or 0.2 nM MTX for 5 min at 37°C, washed and incubated with the fluorochrome inhibitor of caspase-1, green fluorescent peptide 5-carboxyfluorescein-Tyr-Val-Ala-Asp-fluoromethyl ketone (FAM-YVAD-fmk), according to the manufacturer's recommendations (Immunochemistry Technologies). Cells were fixed with 4% formaldehyde, blocked, permeabilized and co-stained for F-actin (phalloidin-Texas Red), ASC or cathepsin L. All coverslips were mounted on slides with ProLong Gold Antifade Reagent (Invitrogen). Images were acquired at room temperature on a Delta Vision RT (Applied Precision) restoration microscope using a 60x/1.42 Plan Apo or 100x/1.40 Uplan Apo objectives and the 360/475 nm, 490/528 nm and 555/617 nm filter sets (Chroma 86000v2). The images were collected using a Coolsnap HQ (Photometrics) camera with a Z optical spacing of 0.2  $\mu$ m. Raw images were then deconvolved using Softworx software and maximum intensity projections of these deconvolved images are shown in the results. ImageJ software (<http://rsb.info.nih.gov/ij/>) was used to quantify images.

### Quantitative reverse transcriptase-PCR analysis

Detailed methods used for qRT-PCR have been described earlier (Pelegrin and Surprenant, 2006). Specific primers were purchased from Qiagen (QuantiTech Primer Assays), for each primer set the efficiency was >95% and a single product was seen on melt curve analysis. Relative expression levels were calculated using the 2<sup>- $\Delta\Delta$ Ct</sup> method normalizing to GAPDH expression levels for each treatment and the fold increase in expression was relative to the smallest expression level.

### Caspase-1 activity and reactive oxygen species measurement

Macrophages were plated in a 96-well plate black with clear bottom and primed to reach different polarity states. For caspase-1 activity, cells were pre-incubated with 37.5  $\mu$ M TMR-YVADAC(AD) at 37°C for 1 h and washed twice with E-total. Fluorescence was recorded using FlexStation 3 over 30 min at 1 min intervals at 380 nm for excitation and 525 nm for the emission. ATP (5 mM) was added into

the wells automatically by the machine at designated time points. For ROS generation, polarized macrophages were washed with PBS and incubated with ATP, clodronate, PPI (0.1–5 mM) or *N*-acetyl cysteine (20 mM) and/or MTX (0.2 nM) in the presence of 10 µg/ml H<sub>2</sub>HFF-BSA and fluorescence emission by the oxidation of H<sub>2</sub>HFF-BSA was recorded by FlexStation 3 over 60 min at 1 min intervals at 492 nm for excitation and 520 nm for the emission.

### Statistical analysis

Average results are expressed as the mean ± s.e.m. from the number of assays indicated (from at least three separate cultures). Data were analysed by an unpaired two-tailed Student's *t*-test to determine difference between groups using Prism and InStat (GraphPad) software.

## References

- Arend WP, Gordon DF, Wood DM, Janson RW, Joslin FG, Jameel S (1989) IL-1 beta production in cultured human monocytes is regulated at multiple levels. *J Immunol* **143**: 118–126
- Brough D, Rothwell N (2007) Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. *J Cell Sci* **120**: 772–781
- Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN (2005) Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. *Pain* **114**: 386–396
- Dinarello CA (1996) Biologic basis for interleukin-1 in disease. *Blood* **87**: 2095–2147
- Dombrecht EJ, De Tollenaere CB, Aerts K, Cos P, Schuerwegh AJ, Bridts CH, Van Offel JF, Ebo DG, Stevens WJ, De Clerck LS (2006) Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation. *Biochem Biophys Res Commun* **348**: 459–464
- Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science* **320**: 674–677
- Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, Gaasterland T, Schoolnik G, Nathan C (2001) Reprogramming of the macrophage transcriptome in response to interferon-gamma and *Mycobacterium tuberculosis*: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. *J Exp Med* **194**: 1123–1140
- Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F (2006) The P2X7 receptor: a key player in IL-1 processing and release. *J Immunol* **176**: 3877–3883
- Gordon S (2003) Alternative activation of macrophages. *Nat Rev Immunol* **3**: 23–35
- Gratchev A, Kzhyskowska J, Köthe K, Muller-Molinat I, Kannookadan S, Utikal J, Goerd S (2006) Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. *Immunobiology* **211**: 473–486
- Hewinson J, Moore SF, Glover C, Watts AG, MacKenzie AB (2008) A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes. *J Immunol* **180**: 8410–8420
- Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF (2006) A-740003 [N-(1-{{(cyanoimino)(5-quinolinylamino) methyl} amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. *J Pharmacol Exp Ther* **319**: 1376–1385
- Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K, Fitzgerald KA, Latz E (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat Immunol* **9**: 847–856
- Kachur AV, Manevich Y, Biaglow JE (1997) Effect of purine nucleoside phosphates on OH-radical generation by reaction of Fe<sup>2+</sup> with oxygen. *Free Radic Res* **26**: 399–408
- Kanneganti TD, Ozören N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P,

### Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

## Acknowledgements

We thank Elizabeth Martin, Austen Sitko and Mari-Carmen Banos-Gregori for technical support. This work was supported by the Wellcome Trust.

## Conflict of interest

The authors declare that they have no conflict of interest.

- Bertin J, Coyle A, Grant E, Akira S, Nunez G (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. *Nature* **440**: 233–236
- Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA (2002) Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. *J Immunol* **168**: 6436–6445
- Maksymowych WP (2002) Bisphosphonates—anti-inflammatory properties. *Curr Med Chem* **1**: 15–28
- Mariathasan S, Newton K, Monack DM, Vucic D, French D, Lee WP, Roose-Girma M, Erickson S, Dixit VM (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. *Nature* **430**: 213–218
- Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* **440**: 228–232
- Martinez FO, Gordon S, Locati M, Mantovani A (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J Immunol* **177**: 7303–7311
- Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. *Front Biosci* **13**: 453–461
- Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* **10**: 417–426
- Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* **440**: 237–241
- McInnes IB, Snell NJ, Perrett JH, Parmar H, Wang MM, Astbury C (2007) Results of a Phase II clinical trial of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (CREATE study). *ACR/ARHP Annual Scientific Meeting presentation* 2085
- Pelegrin P (2008) Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. *Drug News Perspect* **21**: 424–433
- Pelegrin P, Barroso-Gutierrez C, Surprenant A (2008) P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. *J Immunol* **180**: 7147–7157
- Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. *EMBO J* **25**: 5071–5082
- Pelegrin P, Surprenant A (2007) Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. *J Biol Chem* **282**: 2386–2394
- Pennanen N, Lapinjoki S, Urtti A, Monkkonen J (1995) Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells *in vitro*. *Pharm Res* **12**: 916–922
- Pétrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. *Cell Death Differ* **14**: 1583–1589
- Pfeiffer ZA, Aga M, Prabhu U, Watters JJ, Hall DJ, Bertics PJ (2004) The nucleotide receptor P2X7 mediates actin reorganization and membrane blebbing in RAW 264.7 macrophages via p38 MAP kinase and Rho. *J Leukoc Biol* **75**: 1173–1182



- Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G (2005) Macrophage activation switching: an asset for the resolution of inflammation. *Clin Exp Immunol* **142**: 481–489
- Romagnani S (2000) T-cell subsets (Th1 versus Th2). *Ann Allergy Asthma Immunol* **85**: 9–18
- Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int* **19**: 733–759
- Scotton CJ, Martinez FO, Smelt MJ, Sironi M, Locati M, Mantovani A, Sozzani S (2005) Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. *J Immunol* **174**: 834–845
- Serretti R, Core P, Muti S, Salaffi F (1993) Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils. *Rheumatol Int* **13**: 135–138
- Stout RD, Suttles J (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. *J Leukoc Biol* **76**: 509–513
- van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of actions, preparation of liposomes and application. *J Immunol Methods* **174**: 83–93
- van Rooijen N, Sanders A (1997) Elimination, blocking and activation of macrophages: three of a kind? *J Leukoc Biol* **62**: 702–709
- Verhoef PA, Kertesz SB, Estacion M, Schilling WP, Dubyak GR (2004) Maitotoxin induces biphasic interleukin-1beta secretion and membrane blebbing in murine macrophages. *Mol Pharmacol* **66**: 909–920
- Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. *Naunyn Schmiedebergs Arch Pharmacol* **362**: 299–309



**The EMBO Journal is published by Nature Publishing Group on behalf of European Molecular Biology Organization. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Licence. [<http://creativecommons.org/licenses/by-nc-nd/3.0>]**